Roy van der Meel is a biomedical engineer specialized in nanomedicine and RNA therapeutics. After obtaining a PhD from Utrecht University, he moved to Pieter Cullis’ lab at the University of British Columbia where he gained extensive experience with lipid nanoparticle technology. In 2019, Roy was recruited to Eindhoven University of Technology by Willem Mulder, where he is currently appointed Associate Professor in the Precision Medicine group. Roy’s research is supported by a Dutch Research Council (NWO) Vidi Grant and a European Research Council (ERC) Consolidator grant, focusing on engineering RNA-based nanomedicines to precisely regulate immune cell function, aiming to treat diseases like cancer and autoimmune disorders. He has co-authored over 60 publications in journals including Nature Nanotechnology, Nature Biomedical Engineering, Journal of Controlled Release, and ACS Nano, and he was awarded the Controlled Release Society Young Investigator Award in 202